News

The clinical trial is expected to begin in the first half of 2016. PLX-R18 is Pluristem’s second cell therapy product cleared for clinical studies by the U.S. FDA.

The agreement gives Novartis access to four pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumor microenvironment. These programs will be

The companies will partner in a phase 2 study to evaluate the safety and efficacy of the combination of BioLineRx’s BL-8040 CXCR4 antagonist and Merck’s Keytruda humanized monoclonal

TAF is a novel, once-daily, targeted prodrug of tenofovir that showed high antiviral efficacy similar to and at a dose less than one-tenth that of Gilead’s Viread (tenofovir

The US Food and Drug Administration (FDA) has granted priority review for venetoclax to treat CLL in adults who have received at least one prior therapy, including patients

Under terms of the agreement, Merck, through a subsidiary, will acquire IOmet, including its comprehensive pre-clinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors. Based

Under the agreement, Sorrento will sponsor preclinical and clinical research & development programs focused on NK biology as well as adoptive NK cell therapies and, in return, obtain

"This study is designed to use a risk-based approach to treat younger patients with AML," said Professor Nigel Russell, Centre for Clinical Haematology, Nottingham University Hospital, the trial’s

AAA will focus on developing this treatment and its companion diagnostic for prostate cancer through novel molecular nuclear medicine techniques similar to those implemented for the development of